Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61


Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein.

Dua P, Kang HS, Hong SM, Tsao MS, Kim S, Lee DK.

Cancer Res. 2013 Mar 15;73(6):1934-45. doi: 10.1158/0008-5472.CAN-12-3682. Epub 2013 Mar 6.


Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.

Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR.

J Clin Invest. 2012 May;122(5):1734-41. doi: 10.1172/JCI62385. Epub 2012 Apr 9.


Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.

Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H.

Cancer Sci. 2006 Nov;97(11):1191-7. Epub 2006 Aug 17.


Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR, Friess H.

Cancer Biol Ther. 2005 Jul;4(7):740-6. Epub 2005 Jul 5.


Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.


Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis.

Kashiwaya K, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y, Nakamura Y, Nakagawa H.

Cancer Sci. 2009 Mar;100(3):457-64. doi: 10.1111/j.1349-7006.2008.01058.x. Epub 2008 Dec 16.


Selection of aptamers for molecular recognition and characterization of cancer cells.

Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P, Chen HW, Li Y, Tan W.

Anal Chem. 2007 Jul 1;79(13):4900-7. Epub 2007 May 27.


EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.

Iiizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, Katagiri T, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H.

Cancer Sci. 2006 Nov;97(11):1211-6. Epub 2006 Sep 5.


Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX.

Li S, Xu H, Ding H, Huang Y, Cao X, Yang G, Li J, Xie Z, Meng Y, Li X, Zhao Q, Shen B, Shao N.

J Pathol. 2009 Jul;218(3):327-36. doi: 10.1002/path.2543.


Nucleic acid aptamers targeting cell-surface proteins.

Dua P, Kim S, Lee DK.

Methods. 2011 Jun;54(2):215-25. doi: 10.1016/j.ymeth.2011.02.002. Epub 2011 Feb 12. Review.


Aptamers: potential applications to pancreatic cancer therapy.

Rialon KL, White RR.

Anticancer Agents Med Chem. 2011 Jun;11(5):434-41. Review.


Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis.

Kayed H, Kleeff J, Keleg S, Felix K, Giese T, Berger MR, Büchler MW, Friess H.

Cancer Lett. 2007 Jan 8;245(1-2):171-83. Epub 2006 Feb 20.


BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion.

Kayed H, Bekasi S, Keleg S, Michalski CW, Giese T, Friess H, Kleeff J.

Mol Cancer. 2007 Dec 28;6:83. doi: 10.1186/1476-4598-6-83.


Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma.

Champanhac C, Teng IT, Cansiz S, Zhang L, Wu X, Zhoa Z, Fu T, Tan W.

Sci Rep. 2015 Nov 25;5:16788. doi: 10.1038/srep16788.


Applications of aptamers in cancer cell biology.

Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W.

Anal Chim Acta. 2008 Jul 28;621(2):101-8. doi: 10.1016/j.aca.2008.05.031. Epub 2008 May 21. Review.


DNA aptamers as molecular probes for colorectal cancer study.

Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W.

PLoS One. 2010 Dec 10;5(12):e14269. doi: 10.1371/journal.pone.0014269.


Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells.

Pan Z, Erkan M, Streit S, Friess H, Kleeff J.

Int J Oncol. 2009 Oct;35(4):823-8.


Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.

Stephens B, Han H, Hostetter G, Demeure MJ, Von Hoff DD.

Mol Cancer Ther. 2008 Jan;7(1):202-10. doi: 10.1158/1535-7163.MCT-07-0542. Epub 2008 Jan 9.


Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.

Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima Y, Morita S, Endo I, Maeda S, Nakajima A, Nakagama H.

Cancer Sci. 2011 Nov;102(11):2029-37. doi: 10.1111/j.1349-7006.2011.02053.x. Epub 2011 Sep 13.


Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia.

Kayashima T, Nakata K, Ohuchida K, Ueda J, Shirahane K, Fujita H, Cui L, Mizumoto K, Tanaka M.

Cancer Sci. 2011 Jun;102(6):1137-43. doi: 10.1111/j.1349-7006.2011.01936.x. Epub 2011 Apr 27.

Supplemental Content

Support Center